动脉高血压:新的药理目标和未来的前景
Irene Paula Popa1, Andreea Clim1, Alin Constantin Pînzariu1
1Department of Morpho-Functional Sciences II, Discipline of Physiology, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iași, Romania.
Journal of clinical medicine
|October 16, 2024
概括
动脉高血压 (HTN) 管理面临着低血压控制率的挑战. 本综述探讨了有效治疗高血压的新药学目标和干预策略.
科学领域:
- 心脏病学和高血压研究研究
- 药理学和治疗学 药理学和治疗学
- 公共卫生和流行病学
背景情况:
- 动脉高血压 (HTN) 是导致心血管疾病和死亡的全球主要原因,通常因糖尿病和肥胖等并发症而复杂化.
- 尽管有治疗方法,但达到足够的血压控制仍然是一个重大挑战,影响重要器官.
- 目前的医疗保健专注于药理和非药理的HTN管理策略.
研究的目的:
- 审查动脉高血压治疗的新药学标.
- 讨论对抗性高血压的新兴干预技术.
- 探索HTN管理策略中的未来前景.
主要方法:
- 对当前和新兴抗高血压疗法的文献综述.
- 对解决HTN病理生理学和并发症的新药学标的分析.
- 对耐火性高血压病例的干预程序的评估.
主要成果:
- 重要的研究旨在开发针对不同生理病理机制的新药.
- 干预技术为患有不受控制的血压或药物不耐受症的患者提供了替代方案.
- 药物坚持不佳凸显了除传统药物之外的替代治疗方法的需要.
结论:
- 新的药理目标和干预方法对于改善高血压控制至关重要.
- 未来的HTN治疗策略必须解决药物坚持问题,并探索各种治疗途径.
- 持续的研究对于克服当前抗高血压治疗的局限性至关重要.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
137
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
137
Hypertension II: Pathophysiology
2
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
2
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
143
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
143
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
Antihypertensive Drugs: Direct Renin Inhibitors
505
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
505
Hypertension IV: Drug Therapy and Lifestyle Modifications
3
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
3


